2Miettinen M,Sobin LH,Sarlomo-Rikala M.Immunohistochemieal spectrum of gastrointestinal stromal tumors at different sites and their differential diagnosis with other tumors with a special reterence to CD117 (KIT)[J].Mod Pathol,2000,13(10),1134-1142.
4DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
5Mudan SS,Colon KC,Woodruff JM,et al.Salvage surgery for patients with recurrent gastrointestinal sarcoma:prognostic factors to guide patient selection[J].Cancer,2000,88(1):66-74.
6Edmonson JH.Contrast of response to dacarbazine,mitomycin,doxorubicin,and cisptatin (DMAP) plus GM-CSF between patients with advanced malignant gastrniutcstinal stromal tumors and patients with other advanced leiomyosarcomas[J].Cancer Invest,2002,20(5-6):605-612.
7Demetri GD,Von Mehmen M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
